Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Diabetes Reviews

• Publication date

  2013-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/15733998113099990065PMID 23746081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A second chance for a PPARγ targeted therapy?

  2012cited by this paper
• Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

  2012cited by this paper
• Brain PPARγ Promotes Obesity and is Required for the Insulin–Sensitizing Effect of Thiazolidinediones

  2011cited by this paper
• A role for CNS PPARγ in the regulation of energy balance

  2011cited by this paper
• Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation

  2011cited by this paper
• PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

  2011cited by this paper
• Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel‐group study in patients with type 2 diabetes on stable insulin therapy

  2011cited by this paper
• Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

  2011cited by this paper
• Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands

  2010cited by this paper
• 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.

  2010cited by this paper
• Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance.

  2010cited by this paper
• Dietary fats and prevention of type 2 diabetes.

  2009cited by this paper
• MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.

  2009cited by this paper
• Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.

  2009cited by this paper
• INT131: A Selective Modulator of PPARγ

  2009cited by this paper
• INT131: a selective modulator of PPAR gamma.

  2009cited by this paper
• Virtual Screening as a Technique for PPAR Modulator Discovery

  2009cited by this paper
• Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

  2008cited by this paper
• Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1*

  2008cited by this paper
• PPARs and molecular mechanisms of transrepression.

  2007cited by this paper
• Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.

  2007cited by this paper
• Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.

  2007cited by this paper
• Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice.

  2006cited by this paper
• Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.

  2006cited by this paper
• PGC-1α: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes

  2006cited by this paper
• Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma.

  2006cited by this paper
• PGC-1alpha: a key regulator of energy metabolism.

  2006cited by this paper
• Halofenate Is a Selective Peroxisome Proliferator–Activated Receptor γ Modulator With Antidiabetic Activity

  2006cited by this paper
• Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes.

  2006cited by this paper
• A Selective Peroxisome Proliferator-Activated Receptor γ Modulator with Distinct Fat Cell Regulation Properties

  2006cited by this paper
• Combinatorial roles of nuclear receptors in inflammation and immunity

  2006cited by this paper
• Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.

  2006cited by this paper
• n-3 fatty acids and gene expression.

  2006cited by this paper
• Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

  2006cited by this paper
• PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes.

  2006cited by this paper
• Retinoid x receptor heterodimers in the metabolic syndrome.

  2005cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes mellitus

  2005cited by this paper
• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

  2005cited by this paper
• PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1.

  2005cited by this paper
• Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.

  2005cited by this paper
• Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase.

  2005cited by this paper
• The many faces of PPARgamma.

  2005cited by this paper
• [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].

  2004cited by this paper
• Intramyocellular lipids and insulin resistance

  2004cited by this paper
• The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.

  2004cited by this paper
• Network biology: understanding the cell's functional organization

  2004cited by this paper
• Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells.

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Role of Peroxisome Proliferator-Activated Receptor-γ in the Glucose-Sensing Apparatus of Liver and β-Cells

  2004cited by this paper
• Recent advances in peroxisome proliferator-activated receptor science.

  2003cited by this paper
• Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

  2003cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Muscle-specific Pparg deletion causes insulin resistance

  2003cited by this paper
• Thiazolidinediones Block Fatty Acid Release by Inducing Glyceroneogenesis in Fat Cells*

  2003cited by this paper
• A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.

  2003cited by this paper
• Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity.

  2003cited by this paper
• A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease

  2003cited by this paper
• PPAR(gamma) and glucose homeostasis.

  2003cited by this paper
• Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

  2003cited by this paper
• Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells.

  2002cited by this paper
• Peroxisomal Proliferator-Activated Receptor-γ Upregulates Glucokinase Gene Expression in β-Cells

  2002cited by this paper
• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  2002cited by this paper
• Regulation of Pancreatic β-Cell Glucokinase: From Basics to Therapeutics

  2002cited by this paper
• Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.

  2002cited by this paper
• [Diabetes and cardiovascular disease. A comprehensive insight to the new epidemic of the 21st century].

  2002cited by this paper
• A futile metabolic cycle activated in adipocytes by antidiabetic agents

  2002cited by this paper
• Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics.

  2002cited by this paper
• Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

  2002cited by this paper
• New perspectives into the molecular pathogenesis and treatment of type 2 diabetes.

  2001cited by this paper
• Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter.

  2000cited by this paper
• A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.

  2000cited by this paper
• Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men

  1999cited by this paper
• Troglitazone Combination Therapy in Obese Type 2 Diabetic Patients Poorly Controlled with α-Glucosidase Inhibitors

  1999cited by this paper
• A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

  1999cited by this paper
• Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism

  1999cited by this paper
• Identification of a Functional Peroxisome Proliferator-responsive Element in the Murine Fatty Acid Transport Protein Gene*

  1999cited by this paper
• Current Views on the Mechanism of Action of Thiazolidinedione Insulin Sensitizers

  1999cited by this paper
• PPARgamma, the ultimate thrifty gene.

  1999cited by this paper
• PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

  1999cited by this paper
• Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.

  1999cited by this paper
• Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma.

  1998cited by this paper
• Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ

  1998cited by this paper
• Diabetes mellitus and the nervous system

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.

  1998cited by this paper
• Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats*

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression.

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

  1998cited by this paper
• Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.

  1998cited by this paper
• DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements

  1997cited by this paper
• Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ

  1997cited by this paper
• Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

  1996cited by this paper
• PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.

  1996cited by this paper
• Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.

  1996cited by this paper
• Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.

  1996cited by this paper
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  1995cited by this paper
• Occupational therapy and the person with diabetes and vision impairment.

  1995cited by this paper
• Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms.

  1995cited by this paper

• Fungal Melanin as a Potential Geroprotector: First In Vitro Insights

  2025cites this paper
• Cancer prevention and interception with antidiabetic and anti-obesity drugs: current and future perspectives.

  2025cites this paper
• Melanins: functional properties and application possibilities in medical practice

  2024cites this paper
• The Neuroprotective Mechanisms of PPAR‐γ: Inhibition of Microglia‐Mediated Neuroinflammation and Oxidative Stress in a Neonatal Mouse Model of Hypoxic‐Ischemic White Matter Injury

  2024cites this paper
• Rational design of stapled helical peptides as antidiabetic PPARγ antagonists to target coactivator site by decreasing unfavorable entropy penalty instead of increasing favorable enthalpy contribution

  2022cites this paper
• Bioinformatics Study of Pioglitazone Analogues as Potential Anti-Diabetic Drugs

  2022cites this paper
• Peroxisome Proliferator-Activated Receptor γ, but Not α or G-Protein Coupled Estrogen Receptor Drives Functioning of Postnatal Boar Testis—Next Generation Sequencing Analysis

  2021cites this paper
• IN SILICO DESIGN OF QUINOXALINE BEARING THIAZOLIDINONE DERIVATIVES AS PPARγ AGONIST IN DIABETES MELLITUS

  2021cites this paper
• Influence of Nutritional Intake of Carbohydrates on Mitochondrial Structure, Dynamics, and Functions during Adipogenesis

  2020cites this paper
• Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib.

  2020cites this paper
• PPARγ Transcription Deficiency Exacerbates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance in Mice

  2020cites this paper
• Structure Based Virtual Screening, Design, Synthesis and Biological Evaluation of Imidazoles as Anti-Diabetic Agents

  2020cites this paper
• Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure

  2019cites this paper
• PPARgamma agonists sensitize PTEN‐deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy

  2018cites this paper
• Adipocyte-Derived Exosomal MiR-27a Induces Insulin Resistance in Skeletal Muscle Through Repression of PPARγ

  2018cites this paper
• Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma

  2018cites this paper
• A deeper exploration of the relationship between the miR-27a and insulin resistance

  2018cites this paper
• The Effect of Apigenin on the Receptor for Advanced Glycation End Products Gene Expression in Human THP-1 Macrophages and Its Implications for Diabetic Nephropathy Related Inflammation

  2018influential citation
• THIAZOLIDINE-2,4-DIONES: AN UPDATE REVIEW OF ANTIDIABETIC AGENTS

  2018influential citation
• Dijabetes i debljina – začarani krug

  2018cites this paper
• Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome

  2017cites this paper
• Protective effects of pioglitazone on vascular endothelial cell dysfunction induced by high glucose via inhibition of IKKα/β-NFκB signaling mediated by PPARγ in vitro.

  2017cites this paper
• Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

  2016cites this paper
• The vulnerable vessel

  2015cites this paper
• GSK‐3β Phosphorylation of Cytoplasmic Dynein Reduces Ndel1 Binding to Intermediate Chains and Alters Dynein Motility

  2015cites this paper
• Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway.

  2015cites this paper
• Stimulation of nuclear receptor peroxisome proliferator–activated receptor‐γ limits NF‐κB‐dependent inflammation in mouse cystic fibrosis biliary epithelium

  2015cites this paper
• PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.

  2015cites this paper
• The Molecular Mechanisms of Action of Two Drug Candidates for the Treatment of Myocardial Infarction and Sepsis

  2015cites this paper
• The Molecular Mechanisms of Action of Two Drug Candidates for the Treatment of Myocardial Infarction and Sepsis

  2015cites this paper